Anastasia Marysheva
Research Subjects
Anastasia Marysheva has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay Krotenko
S.S. Yudin City Clinical Hospital, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia
5 shared publications - Olga Viktorovna Ignatenko
Sergey Yudin City Clinical Hospital, Moscow, Russia;Russian Medical Academy of Continuous Professional Education, Moscow, Russia;Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
5 shared publications - Anastasia Doronenkova
S.S. Yudin City Clinical Hospital, Moscow, Russia
4 shared publications - I. A. Zaigrayev
Sergey Yudin City Clinical Hospital, Moscow, Russia;National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
4 shared publications - Lev A. Krichevskiy
S.S. Yudin City Clinical Hospital, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia
4 shared publications - Marina Grinenko
S.S. Yudin City Clinical Hospital, Moscow, Russia
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Prognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Open AccessPrognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Prognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Open AccessPrognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 73-85
Combined extracorporeal therapy with plasma exchange and hemoadsorbtion in septic shock: a randomized controlled study
INTRODUCTION: The consistently high mortality rate associated with septic shock leads to the search for new treatment strategies. OBJECTIVE: The aim of our study was to analyze the efficacy and safety of the combined use of plasma exchange and hemosorbtion in septic shock. MATERIALS AND METHODS: A total of 64 patients with septic shock who were hospitalized in the ICU of the S.S. Yudin Hospital in Moscow from January 2023 to January 2024 were prospectively examined. The combined extracorporeal therapy group included patients who underwent two combinations of procedures depending on the level of endotoxinactivity (endotoxin activity assay — EAA): with EAA greater than 0.6 — plasma exchange + LPS hemosorbtion, with EAA less than 0.6 — plasma exchange + cytokine hemosorption. The controlgroup included patients with standard sepsis therapy. Clinical and laboratory parameters, duration and outcomes of intensive care were recorded. RESULTS: The study group (ET, n = 31), compared with the control group (n = 33), was characterized by a significant (p < 0.05) reduction of organ disfunction according to the Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation II, scales, a decrease of systemic inflammation markers, and an increase of IgG level within 72 hours after inclusion in the study. Hospital mortality was lower in the ET group than in the control group 32 and 58 %, respectively: OR 0.35; 95% CI 0.12–0.98; p = 0.023. CONCLUSIONS: Combined extracorporeal therapy is an effective treatment strategy for septic shock, improving the results of its intensive care.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 73-85
Open AccessCombined extracorporeal therapy with plasma exchange and hemoadsorbtion in septic shock: a randomized controlled study
INTRODUCTION: The consistently high mortality rate associated with septic shock leads to the search for new treatment strategies. OBJECTIVE: The aim of our study was to analyze the efficacy and safety of the combined use of plasma exchange and hemosorbtion in septic shock. MATERIALS AND METHODS: A total of 64 patients with septic shock who were hospitalized in the ICU of the S.S. Yudin Hospital in Moscow from January 2023 to January 2024 were prospectively examined. The combined extracorporeal therapy group included patients who underwent two combinations of procedures depending on the level of endotoxinactivity (endotoxin activity assay — EAA): with EAA greater than 0.6 — plasma exchange + LPS hemosorbtion, with EAA less than 0.6 — plasma exchange + cytokine hemosorption. The controlgroup included patients with standard sepsis therapy. Clinical and laboratory parameters, duration and outcomes of intensive care were recorded. RESULTS: The study group (ET, n = 31), compared with the control group (n = 33), was characterized by a significant (p < 0.05) reduction of organ disfunction according to the Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation II, scales, a decrease of systemic inflammation markers, and an increase of IgG level within 72 hours after inclusion in the study. Hospital mortality was lower in the ET group than in the control group 32 and 58 %, respectively: OR 0.35; 95% CI 0.12–0.98; p = 0.023. CONCLUSIONS: Combined extracorporeal therapy is an effective treatment strategy for septic shock, improving the results of its intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- Open Access
- 30 October 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 4,p. 60-71
Dynamics of organ dysfunction and inflammation markers in patients with septic shock during multimodal hemocorrection: a multicenter, randomized, controlled study
INTRODUCTION: Septic shock is the most serious complication in intensive care that associates with significant mortality. Extracorporeal hemocorrection may improve treatment of patients with septic shock. OBJECTIVE: Evaluation of the effect of hemocorrection with the multimodal adsorbent device Efferon LPS on the dynamics of organ dysfunction and inflammation markers in patients with septic shock. MATERIALS AND METHODS: A multicenter randomized controlled study was conducted in four clinical organizations in the city of Moscow from March 2021 to May 2022. The study included 58 patients (29 men and 29 women) with septic shock. Randomization was performed in a ratio of 2:1 (hemoperfusion: control). Within 24 hours of enrollment in the study, selective hemoperfusion procedures were performed or standard therapy was used. Hemosorption using Efferon LPS was performed twice, with an interval of 24.5 (23.3–26.0) hours. RESULTS: The use of the multimodal selective hemosorbent Efferon LPS significantly reduced the severity of multiple organ failure (MOF) in patients with septic shock from 7 to 3 points on the SOFA scale after 72 hours by improving hemodynamics, respiratory and renal function. In contrast to the control group, in the Efferon LPS group, the levels of CRP, PCT and IL-6 significantly decreased in 72 hours. The severity of MOF significantly correlated with the level of CRP and PCT (Spearman’s r = 0.346 and r = 0.444, respectively). The duration of hospitalization in survived patients was 16.1 days and 30.1 days in the Efferon LPS and control group, respectively (p = 0.032). The need for a renal replacement therapy (RRT) in survivors by the 3rd day was significantly reduced only in the Efferon LPS group — from 73.7 to 33.3 %. CONCLUSIONS: The use of the selective hemosorbent Efferon LPS resulted in significant decreases the hallmarks of systemic inflammation, MOF and requirements for RRT in patients with septic shock.
- 30 October 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 4,p. 60-71
Open AccessDynamics of organ dysfunction and inflammation markers in patients with septic shock during multimodal hemocorrection: a multicenter, randomized, controlled study
INTRODUCTION: Septic shock is the most serious complication in intensive care that associates with significant mortality. Extracorporeal hemocorrection may improve treatment of patients with septic shock. OBJECTIVE: Evaluation of the effect of hemocorrection with the multimodal adsorbent device Efferon LPS on the dynamics of organ dysfunction and inflammation markers in patients with septic shock. MATERIALS AND METHODS: A multicenter randomized controlled study was conducted in four clinical organizations in the city of Moscow from March 2021 to May 2022. The study included 58 patients (29 men and 29 women) with septic shock. Randomization was performed in a ratio of 2:1 (hemoperfusion: control). Within 24 hours of enrollment in the study, selective hemoperfusion procedures were performed or standard therapy was used. Hemosorption using Efferon LPS was performed twice, with an interval of 24.5 (23.3–26.0) hours. RESULTS: The use of the multimodal selective hemosorbent Efferon LPS significantly reduced the severity of multiple organ failure (MOF) in patients with septic shock from 7 to 3 points on the SOFA scale after 72 hours by improving hemodynamics, respiratory and renal function. In contrast to the control group, in the Efferon LPS group, the levels of CRP, PCT and IL-6 significantly decreased in 72 hours. The severity of MOF significantly correlated with the level of CRP and PCT (Spearman’s r = 0.346 and r = 0.444, respectively). The duration of hospitalization in survived patients was 16.1 days and 30.1 days in the Efferon LPS and control group, respectively (p = 0.032). The need for a renal replacement therapy (RRT) in survivors by the 3rd day was significantly reduced only in the Efferon LPS group — from 73.7 to 33.3 %. CONCLUSIONS: The use of the selective hemosorbent Efferon LPS resulted in significant decreases the hallmarks of systemic inflammation, MOF and requirements for RRT in patients with septic shock.